Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma

被引:30
作者
Groeschl, Ryan T. [1 ]
Miura, John T. [1 ]
Wong, Ray K. [1 ]
Bloomston, Mark [2 ]
Lidsky, Michael L. [3 ]
Clary, Bryan M. [3 ]
Martin, Robert C. G. [4 ]
Belli, Giulio [5 ]
Buell, Joseph F. [6 ]
Gamblin, T. Clark [1 ]
机构
[1] Med Coll Wisconsin, Div Surg Oncol, Milwaukee, WI 53226 USA
[2] Ohio State Univ, Div Surg Oncol, Columbus, OH 43210 USA
[3] Duke Univ, Med Ctr, Div Surg Oncol, Durham, NC USA
[4] Univ Louisville, Div Surg Oncol, Louisville, KY 40292 USA
[5] Loreto Nuovo Hosp, Dept Surg, Naples, Italy
[6] Tulane Univ, Tulane Abdominal Transplant Inst, New Orleans, LA 70118 USA
关键词
liver; neoplasms; cancer; hepatectomy; surgery; hepatocellular; CONVENTIONAL HEPATOCELLULAR-CARCINOMA; CLINICOPATHOLOGICAL FEATURES; LIVER; TRANSPLANTATION; RECOMMENDATIONS; EXPERIENCE; CHILDHOOD; HEPATOMA; TUMORS;
D O I
10.1002/jso.23658
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background and Objectives Fibrolamellar carcinoma (FLC) presents in young, otherwise-healthy individuals. This study examined recurrence and survival characteristics after surgical resection for FLC by utilizing an international multi-institutional database. Methods Consecutive patients undergoing hepatectomy for FLC from six institutions (1993-2010) were reviewed retrospectively. Survival was studied with life tables and Cox regression models. Results Thirty-five patients (13 female, 37%) were included (median age: 32 years). R0 resection was achieved in all curative-intent operations (n=30), and palliative operations were performed for five patients. Crude 30-day morbidity and mortality rates were 22% and 3%, respectively. For curative-intent surgery, overall and recurrence-free survivals at 5 years were 62% and 45%, respectively. In patients who achieved a 4-year disease-free interval after surgery, none subsequently developed recurrence. In multivariate models, presence of extrahepatic disease was the only factor that independently predicted overall (hazard ratio [HR]: 5.58, 95% confidence interval [CI]: 1.38-22.55, P=0.016) and recurrence-free survival (HR: 5.64, 95% CI: 1.48-21.49, P=0.011). Conclusions Patients with surgically amenable FLC had encouraging long-term survival. Recurrence-free survival to 4 years suggested possible freedom from disease thereafter. Recurrent resectable disease was associated with an excellent prognosis, and repeat surgery should be strongly considered. J. Surg. Oncol. 2014; 110:412-415. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:412 / 415
页数:4
相关论文
共 23 条
[1]
Ang Celina S, 2013, Gastrointest Cancer Res, V6, P3
[2]
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report [J].
Clavien, Pierre-Alain ;
Lesurtel, Mickael ;
Bossuyt, Patrick M. M. ;
Gores, Gregory J. ;
Langer, Bernard ;
Perrier, Arnaud .
LANCET ONCOLOGY, 2012, 13 (01) :E11-E22
[3]
Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children [J].
Czauderna, P ;
Zbrzezniak, G ;
Narozanski, W ;
Korzon, M ;
Wyszomirska, M ;
Stoba, C .
PEDIATRIC BLOOD & CANCER, 2006, 46 (07) :825-828
[4]
Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[5]
DIFFERENTIAL DIAGNOSIS OF TUMORS AND TUMOR-LIKE LESIONS OF LIVER IN INFANCY AND CHILDHOOD [J].
EDMONDSON, HA .
AMA JOURNAL OF DISEASES OF CHILDREN, 1956, 91 (02) :168-186
[6]
Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study [J].
El-Serag, HB ;
Davila, JA .
HEPATOLOGY, 2004, 39 (03) :798-803
[7]
Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[8]
Intrahepatic cholangiocardnoma - Rising frequency, improved survival, and determinants of outcome after resection [J].
Endo, Itaru ;
Gonen, Mithat ;
Yopp, Adam C. ;
Dalal, Kimberly M. ;
Zhou, Qin ;
Klimstra, David ;
DAngelica, Michael ;
DeMatteo, Ronald P. ;
Fong, Yuman ;
Schwartz, Lawrence ;
Kemeny, Nancy ;
O'Reilly, Eileen ;
Abou-Alfa, Ghassan K. ;
Shimada, Hiroshi ;
Blumgart, Leslie H. ;
Jarnagin, William R. .
ANNALS OF SURGERY, 2008, 248 (01) :84-96
[9]
Metastatic nonresectable fibrolamellar hepatoma - Prognostic features and natural history [J].
Epstein, BE ;
Pajak, TF ;
Haulk, TL ;
Herpst, JM ;
Order, SE ;
Abrams, RA .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (01) :22-28
[10]
Aggressive Surgical Management of Fibrolamellar Hepatocellular Carcinoma [J].
Hemming A.W. ;
Langer B. ;
Sheiner P. ;
Greig P.D. ;
Taylor B.R. .
Journal of Gastrointestinal Surgery, 1997, 1 (4) :342-346